26
|
Kwant PB, Finocchiaro T, Förster F, Reul H, Rau G, Morshuis M, El Banayosi A, Körfer R, Schmitz-Rode T, Steinseifer U. The MiniACcor: Constructive Redesign of an Implantable Total Artificial Heart, Initial Laboratory Testing and Further Steps. Int J Artif Organs 2018; 30:345-51. [PMID: 17520573 DOI: 10.1177/039139880703000411] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The Aachen Total Artificial Heart (ACcor) has been under development at the Helmholtz Institute in Aachen over the last decade. It may serve as a bridge to transplant or as a long-term replacement of the natural heart. Based upon previous in vivo experiments with the ACcor total artificial heart, it was decided to optimize and redesign the pump unit. Smaller dimensions, passive filling and separability into three components were the three main design goals. The new design is called the MiniACcor, which is about 20% smaller than its predecessor, and weighs only 470 grams. Also its external driver/control unit was miniaturized and a new microcontroller was selected. To validate the design, it was extensively tested in laboratory mock loops. The MiniACcor was able to pump between 4.5 and 7 l/min at different pump rates against normal physiological pressures. Several requirements for the future compliance chamber and transcutaneous energy transmission (TET) system were also measured in the same mock loop. Further optimization and validation are being performed in cooperation with the Heart and Diabetes Centre North Rhine-Westphalia.
Collapse
|
27
|
Sandica E, Blanz U, Ben L, Schultz-Kaizler U, Kececioglu D, Laser K, Kirchner G, zu E, Morshuis M. Bad Oeynhausen Experience with Berlin Heart EXCOR in Children with Single- and Two-Ventricle Physiology. Thorac Cardiovasc Surg 2017. [DOI: 10.1055/s-0037-1598981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
28
|
Pühler T, Fujita B, Renner A, Hakim-Meibodi K, Bögermann J, Morshuis M, Gummert J, Ensminger S. Operative Myokardrevaskularisation bei schlechter linksventrikulärer Funktion – STICH forever? AKTUELLE KARDIOLOGIE 2016. [DOI: 10.1055/s-0042-114219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
29
|
Aissaoui N, Morshuis M, Maoulida H, Salem J, Brunn M, Varnous S, Gummert J, Durand-Zaleski I, Leprince P, Fagon J. Transplantation versus Ventricular Assist Device for the Management of End-Stage Heart Failure: An Observational Comparison of Clinical and Economic Outcomes. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
30
|
Oezpeker C, Morshuis M, Schoenbrodt M, Zittermann A, Gummert J. Permanent Atrial Fibrillation and 1-Year Clinical Outcome in Patients with Left Ventricular Assist Device Implants. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.416] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
31
|
Krabatsch T, Schmitto J, Pya Y, Zimpfer D, Garbade J, Rao V, Morshuis M, Marasco S, Beyersdorf F, Sood P, Damme L, Netuka I. HeartMate 3 Fully Magnetically Levitated Left Ventricular Assist Device for the Treatment of Advanced Heart Failure -1 Year Results from the CE Mark Trial. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
32
|
Haas N, Boergermann J, Laser T, Morshuis M, Kizner L, Gummert J, Kececioglu D, Kantzis M. Emergency Closure of a Traumatic Ventricular Septal Defect (VSD) after a Horse Kick Injury with an 18-mm Occlutech ASD Occluder. Thorac Cardiovasc Surg 2016. [DOI: 10.1055/s-0036-1571943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Oezpeker C, Zittermann A, Schoenbrodt M, Gummert J, Morshuis M. Permanent Atrial Fibrillation and 1-year Clinical Outcome in Patients with Left Ventricular Assist Device Implants. Thorac Cardiovasc Surg 2016. [DOI: 10.1055/s-0036-1571482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
34
|
Oezpeker C, Zittermann A, Paluszkiewicz L, Piran M, Puehler T, Sayin AO, Ensminger S, Milting H, Morshuis M, Gummert JF. Tricuspid valve repair in patients with left-ventricular assist device implants and tricuspid valve regurgitation: propensity score-adjusted analysis of clinical outcome. Interact Cardiovasc Thorac Surg 2015; 21:741-7. [DOI: 10.1093/icvts/ivv260] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Accepted: 08/19/2015] [Indexed: 11/14/2022] Open
|
35
|
Krabatsch T, Morshuis M, Garbade J, Zimpfer D, Potapov E, Laufer G, Mohr F, Falk V, Gummert J. The HeartWare HVAD Pump in Clinical Practice - Results From 1,035 Patients Analyzed in a Retrospective European Multi-Center Study. J Heart Lung Transplant 2015. [DOI: 10.1016/j.healun.2015.01.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
36
|
Potapov E, Garbade J, Hakim-Meibodi K, Strueber M, Gummert J, Mohr F, Falk V, Krabatsch T, Morshuis M. The HeartMate II Pump in Clinical Practice - Results From 479 Patients Analyzed in a Retrospective European Multi-Center Study. J Heart Lung Transplant 2015. [DOI: 10.1016/j.healun.2015.01.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
37
|
Zittermann A, Morshuis M, Kuhn J, Pilz S, Ernst JB, Oezpeker C, Dreier J, Knabbe C, Gummert JF, Milting H. Vitamin D metabolites and fibroblast growth factor-23 in patients with left ventricular assist device implants: association with stroke and mortality risk. Eur J Nutr 2015; 55:305-13. [PMID: 25657014 DOI: 10.1007/s00394-015-0847-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2014] [Accepted: 01/27/2015] [Indexed: 12/29/2022]
Abstract
PURPOSE Stroke and mortality risk in patients with left ventricular assist device (LVAD) implants continue to be high. Whether nonclassical cardiovascular risk markers such as vitamin D metabolites and fibroblast growth factor (FGF)-23 contribute to this risk remains to be studied, and this was the objective of our work. METHODS In 154 LVAD patients (91 HeartWare and 63 HeartMate II implants), we measured circulating 25-hydroxyvitamin D (25OHD), 1,25-dihydroxyvitamin D3 (1,25[OH]2D3), parathyroid hormone (PTH) and FGF-23 shortly before LVAD implantation and investigated their association with stroke and mortality risk during 1-year follow-up. RESULTS Of the study cohort, 34.4 and 92.2%, respectively, had deficient 25OHD (<25 nmol/l) and 1,25(OH)2D3 (<41 pmol/l) values, whereas 42.6 and 98.7%, respectively, had elevated PTH levels (>6.7 pmol/l) and FGF-23 values above the reference range (100 RU/ml). One-year freedom from stroke was 80.9 %, and 1-year survival was 64.3%. The multivariable-adjusted hazard ratio of stroke was 2.44 (95% CI: 1.09-5.45; P = 0.03) for the subgroup of 25OHD levels <25 nmol/l (reference group: 25OHD levels ≥25 nmol/l). The multivariable-adjusted hazard ratio of 1-year mortality was 2.78 (95% CI: 1.52-5.09; P = 0.001) for patients with 25OHD levels <25 nmol/l compared with patients with 25OHD levels ≥25 nmol/l. PTH, FGF-23 and 1,25(OH)2D3 were not associated with stroke or mortality risk. CONCLUSIONS In LVAD patients, deficient 25OHD levels are independently associated with high stroke and mortality risk. If confirmed in randomized controlled trials, preoperative correction of deficient vitamin D status could be a promising measure to reduce stroke and mortality risk in LVAD patients.
Collapse
|
38
|
Oezpeker C, Paluszkiewicz L, Zittermann A, Ensminger S, Gummert J, Morshuis M. Tricuspid Valve Repair in Patients with Left Ventricular Assist Device Implants and Tricuspid Valve Regurgitation: Propensity Score-Adjusted Analysis of Clinical Outcome. Thorac Cardiovasc Surg 2015. [DOI: 10.1055/s-0035-1544490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
39
|
Zittermann A, Morshuis M, Kuhn J, Pilz S, Ernst J, Oezpeker C, Dreier J, Knabbe C, Gummert J, Milting H. Vitamin D Metabolites and Fibroblast Growth Factor-23 in Patients with Left Ventricular Assist Device Implants: Association with Stroke and Mortality Risk. Thorac Cardiovasc Surg 2015. [DOI: 10.1055/s-0035-1544325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
40
|
Özpeker U, Prashovikj E, Rudloff M, Ensminger S, Kizner L, Gummert J, Morshuis M. Extracorporeal Biventricular Support in Intermacs 1 Patients. Thorac Cardiovasc Surg 2015. [DOI: 10.1055/s-0035-1544487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
41
|
Morshuis M, Özpeker C, Schulz U, Gummert J, Koster A. Herzunterstützungssysteminduzierte Störungen der Gerinnung. ZEITSCHRIFT FUR HERZ THORAX UND GEFASSCHIRURGIE 2014. [DOI: 10.1007/s00398-013-1050-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Sandica E, Blanz U, Ben Mime L, Schultz-Kaizler U, Kirchner G, Knyphausen EZ, Lauenroth V, Morshuis M. 280 * LONG-TERM MECHANICAL CIRCULATORY SUPPORT IN PAEDIATRIC PATIENTS: THE BAD OEYNHAUSEN EXPERIENCE. Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu276.280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Ensminger S, Puehler T, Schulz U, Fuchs U, Schönbrodt M, Morshuis M, Börgermann J, Hakim-Meiboudi K, Gummert J. Operative Strategien bei terminaler Herzinsuffizienz. AKTUELLE KARDIOLOGIE 2014. [DOI: 10.1055/s-0034-1368474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
44
|
Özpeker C, Schönbrodt M, Börgermann J, Gummert J, Morshuis M. Management of pump thrombosis: Device exchange versus thrombolysis. Thorac Cardiovasc Surg 2014. [DOI: 10.1055/s-0034-1367121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
45
|
Özpeker C, Morshuis M, Schönbrodt M, Börgermann J, Renner A, Gummert J. Aortic insufficiency development in 391 patients supported with four different cf-LVADs: A single center experience. Thorac Cardiovasc Surg 2014. [DOI: 10.1055/s-0034-1367118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
46
|
Puehler T, Ensminger S, Schulz U, Fuchs U, Tigges-Limmer K, Börgermann J, Morshuis M, Hakim K, Oldenburg O, Niedermeyer J, Renner A, Gummert J. [Heart and combined heart-lung transplantation. Indications, chances and risks]. Herz 2014; 39:66-73. [PMID: 24452762 DOI: 10.1007/s00059-013-4042-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Orthotopic heart transplantation (HTX) is nowadays the worldwide accepted gold standard for the treatment of terminal heart failure. The main indications for HTX are non-ischemic dilatative (54%) and ischemic (37%) heart failure. In the acute phase after HTX the survival rate is approximately 90%. Good short and long-term results with survival rates ranging from 81% after 1 year to more than 50% after 11 years demonstrate that there is currently no real treatment alternative to HTX for treatment of end-stage heart failure. In the case of irreversible pulmonary hypertension in combination with end-stage heart failure or complex congenital heart syndromes, a combined heart and lung transplantation (HLTX) is necessary. Compared with HTX the short-term survival of HLTX is reduced, mostly for technical reasons. Improved long-term results after HTX and HLTX are a result of highly specialized transplantation units and effective immunosuppression. However, a major problem is the shortage of organ donors in Germany and the resulting long waiting times for patients with frequently occurring blood groups of up to 10 months for transplantation. The consequence of the latter is the ever increasing number of implanted cardiac assist devices in patients not only as a bridge to transplant but also as destination therapy.
Collapse
|
47
|
Salem JE, Paluszkiewicz L, Hulot JS, Perdrix L, Morshuis M, Leprince P, Gummert J, Diebold B, Aissaoui N. Impact of inotropic drugs on the validity of left ventricular filling pressure echocardiographic assessment in end-stage heart failure patients. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p1116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
48
|
Schyma C, Doberentz E, Morshuis M, Madea B. Todesfall eines Patienten mit Herzunterstützungssystem. Rechtsmedizin (Berl) 2013. [DOI: 10.1007/s00194-013-0889-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
49
|
Torregrossa G, Gerosa G, Tarzia V, Vida V, Duveau D, Arabia F, Leprince P, Kasirajan V, Beyersdof F, Loforte A, Musumeci F, Hetzer R, Krabatsch T, Gummert J, Morshuis M, Copeland J. Long Term Results with Total Artificial Heart: Is It Prime Time for Destination Therapy? J Heart Lung Transplant 2013. [DOI: 10.1016/j.healun.2013.01.250] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
50
|
Schulz U, Morshuis M, Oezpeker C, Hakim-Meibodi K, Ensminger S, Börgermann J, Gummert J. Impact of Different Indications for HU Listing of VAD Patients on Survival after Heart Transplantation. J Heart Lung Transplant 2013. [DOI: 10.1016/j.healun.2013.01.385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|